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Cerebral malaria is still a deleterious health problem in tropical countries. The wide spread of malarial drug
resistance and the lack of an effective vaccine are obstacles for disease management and prevention. Parasite and
human genetic factors play important roles in malaria susceptibility and disease severity. The malaria parasite
exerted a potent selective signature on the human genome, which is apparent in the genetic polymorphism
landscape of genes related to pathogenesis. Currently, much genomic data and a novel body of knowledge,
including the identification of microRNAs, are being increasingly accumulated for the development of laboratory
testing cassettes for cerebral malaria prevention. Therefore, understanding of the underlying complex molecular
basis of cerebral malaria is important for the design of strategy for cerebral malaria treatment and control.
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Cerebral malaria (CM) is a life-threatening disease that
represents a global health problem particularly in
tropical countries. According to a report of the World
Health Organization (WHO) in the year 2015, malaria
transmission still occurs in approximately 97 countries
and territories, mostly in Sub-Saharan Africa, Southeast
Asia, and South America. In the year 2013, the estimated
incidence of malaria infection was 198 million cases
(range 124–283 million) worldwide. Over 575,000 cases
of CM have been reported. Approximately 584,000 cases
(range 367,000–755,000) died from malaria. African
children are the most affected case of CM. Most of the
malaria-related deaths, approximately 90 %, occurred in
Africa [1]. In Sub-Saharan Africa, 575,000 children with
CM have been annually reported and 110,000 cases died
(approximately 19–25 % case fatality rate). Unfortunately,
>2 % of survivors of CM experienced developmental and
behavioral impairment lasting for 6 months. The disabil-
ity, severity, and neurological duration are critical for CM
management and essential for understanding of CM* Correspondence: pornlada.nuc@mahidol.ac.th
1Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol
University, Bangkok 10700, Thailand
4Center for Research and Innovation, Faculty of Medical Technology, Mahidol
University, Bangkok, Thailand
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zepathogenesis. Due to prevention and control programs,
the morbidity and motility rates of malaria were
reduced globally. In Thailand, the mortality rate
decreased 50–74 % between 2000 and 2013 [1, 2].
Plasmodium falciparum is the causative organism
leading to human CM development. The bite of a P.
falciparum-infected female anopheline mosquito medi-
ates the development of various disease severities ran-
ging from uncomplicated malaria to severe malaria and
CM. Uncomplicated malaria or mild malaria is defined
as a febrile illness without any clinical or laboratory
signs of severity or vital organ dysfunction. Complicated
malaria or severe malaria involves the central nervous
system (cerebral malaria), the pulmonary system (re-
spiratory failure), the renal system (acute renal failure),
and the hematopoietic system (severe anemia). Accord-
ing to the updated definition of severe falciparum mal-
aria by the WHO (2015), severe falciparum malaria is
defined as the presence of P. falciparum asexual parasit-
emia, with one or more clinical features or laboratory
findings (Table 1) and without any identified alternative
causes. The hallmarks of CM are coma (Glasgow Coma
Scale <11, Blantyre coma score <3) or malaria with a
persistent coma [3]. Clinical manifestations of severe
malaria include but are not limited to CM (with inci-
dence rate of 0.9–3.5 per 1000 child-year), severele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 WHO guideline for complicated malaria
Clinical features
- Impaired consciousness: Glasgow Coma Scale <11 in adults or Blantyre
coma score <3 in children
- Prostration
- Multiple convulsion: >2 episodes within 24 h
- Respiratory distress
- Pulmonary edema: radiologically confirmed or oxygen saturation
<92 % in room air with a respiratory rate >30/min
- Significant bleeding: including recurrent or prolonged bleeding
from the nose, gums, and venipuncture sites; hematemesis or melena
- Shock
Laboratory findings
- Metabolic acidosis: plasma bicarbonate <15 mmol/L or venous plasma
lactate ≥5 mmol/L
- Hypoglycemia: blood glucose <2.2 mmol/L or 40 mg/dL
- Severe malarial anemia: Hb <5 g/dL, Hct ≤15 % in children (<12 years
of age) with parasite >10,000/μL; Hb <7 g/dL, Hct ≤20 % in adults
with parasite >10,000/μL
- Renal impairment: plasma or serum creatinine >265 μmol/L (3 mg/dL)
or blood urea >20 mmol/L
- Jaundice: plasma or serum bilirubin >50 μmol/L (3 mg/dL) with
parasite count >10,000/μL
- Hyperparasitemia: P. falciparum parasitemia >10 %
Table 2 Characteristic of P. berghei ANKA strain in mouse
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respiratory failure (1.4–5.4 per 1000 child-year) [1, 2].
Mechanism of CM
The mechanism of CM is not clearly understood. Re-
searchers have exerted extensive efforts to elucidate the
mechanism of CM using several approaches such as in vivo
experimental mouse models [4, 5], in vitro co-cultures of
parasitized red cells with human brain microvascular endo-
thelial cells [6, 7], and postmortem tissue and clinical sam-
ples from patients in endemic areas [8, 9]. For the in vivo
studies, Plasmodium berghei ANKA (PbA)-infected CBA
and C57BL/6 mice have been used as a CM susceptible
model. The mouse model manifests the neurological symp-
toms within 6–14 days after infection and then dies [10].
The differences in the characteristics between the murine
model and humans are the host receptor and the absence
of knob-like structures of the P. falciparum erythrocyte
membrane protein 1 (PfEMP1) (Table 2) [11].
The development of CM is biologically complex and
involves multiple mechanisms such as sequestration,
immunopathology by the pro-inflammatory cytokine
interferon-γ (IFN-γ), tumor necrosis factor alpha (TNF-α),
and apoptosis. Red cell sequestration is an important step in
the development of CM. The binding of PfEMP1 on in-
fected red blood cells to host receptors such as intercellular
adhesion molecule-1 (ICAM-1) and CD36 on brain endo-
thelial cells mediates sequestration [12, 13]. Parasitized red
blood cells (pRBCs) also form rosettes and clumps that im-
pair microcirculation and cause hypoxia, which leads to
neuronal tissue necrosis [14]. The production of IFN-γ from
Th1 cells stimulates monocytes to express higher levels of
the transmembrane form of TNF (memTNF) that interactswith tissue necrotic factor receptor 2 (TNFR2) expressed on
brain endothelial cells causing the up-regulation of ICAM-1
on brain endothelial cells [15]. The up-regulation of ICAM-
I on brain endothelial cells leads to an increase in platelets,
pRBCs, and leukocyte adhesion. This contributes to the fol-
lowing clinical outcomes: (1) vessel obstruction and ische-
mia and (2) vessel disruption and brain hemorrhage. There
are several reports of apoptotic mechanisms in endothelial
cells leading to blood-brain barrier (BBB) dysfunctions in
CM. The consequence of pRBC cytoadherence to the endo-
thelial cell leads to (1) caspase 8 and 9 activation leading to
apoptosis, (2) cytotoxic T cell activation leading to perforin-
mediated cell death [16], (3) TNF-α overproduction as a re-
sult of the glycosylphosphatidylinositol (GPI activates apop-
tosis by inducing NO and oxidative stress) from the
parasite, and (4) NF-kB activation in brain endothelial cells,
neurons, and glial cells resulting in caspase 3 activation [8].
Microparticles are cellular membrane-derived vesicles
generated by cytoskeletal alterations as a result of cellular
membrane remodeling and loss of phospholipid asym-
metry. Under physiological conditions, microparticles
derived from platelets, white blood cells, red blood cells,
and endothelial cells are expressed at normal levels. The
overexpression of microparticles is associated with cell
activation and apoptosis [17]. The ATP-binding cassette
transporter A1 (ABCA1) gene is involved in the process of
microparticle release. ABCA1 gene deletion or knockout
is associated with protection from CM in mice [18, 19].
Moreover, endothelial microparticles (EMPs) and TNF are
increased during coma episodes of CM in Malawian
children compared to the uncomplicated malaria group
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particles in the pathogenesis of CM [17].
The roles of CD8+ T cell in malaria infection are
highlighted in many studies. CD8+ T cell acts as (1)
effector cell in hepatic and erythrocytic phase for malaria
vaccine development [21] and (2) pathogenic cell in ex-
perimental cerebral malaria (ECM) development [22]. In
CM, it was found that dendritic cells (CD8α+ DCs) are re-
sponsible for malaria antigen presentation to CD8+ T cell.
This leads to CD8+ T cell proliferation and cytotoxic T
lymphocyte (CTL) production mediating ECM. The crit-
ical role of CD8α+ DCs as the major antigen-presenting
subset in CM was further demonstrated in the protection
against CM in CD8α+ DC-depleted mice [21]. The role of
CD8+ T cell has been identified as the major mediator of
lethality in ECM via the secretion of perforin and gran-
zymes inducing brain endothelial apoptosis and disruption
of BBB. In addition, the cytoadherence of pRBCs to brain
endothelial cells could lead to malaria antigen uptake via a
trogocytosis-like process [22]. Interestingly, brain endo-
thelial cells of PbA-infected mice produced a large num-
ber of MP which finally resulted in CM pathogenesis [20].
Insight into gene regulation of malaria infection
Gene regulation is a process responsible for controlling
the rate and manner of gene expression. In humans, dys-
functional gene regulation has been demonstrated in
various pathological processes such as inflammatory
responses and metabolic processes. Researchers have
exerted extensive efforts to uncover the genetic regulation
of infectious diseases to develop novel therapeutic agents
that target the critical components, which are essential for
the survival or amplification of the infective agents or
which directly regulate the host immune system. Human
gene expression is mainly regulated at the transcriptional
and translational levels. Moreover, the mechanisms of epi-
genetic regulation of gene expression such as chromatin
remodeling, histone modification, and non-coding RNAs,
particularly microRNAs (miRNAs), have been shown to
play important roles in the pathogenesis of complex
diseases [20].
miRNAs are 21–25 nucleotide single-stranded non-
coding RNA molecules. miRNAs are transcribed from
miRNA genes by RNA polymerase II into long pri-
miRNAs and then cleaved by the enzyme Drosha into
smaller pre-miRNAs. This precursor is subsequently
exported to the cytoplasm by the exportin-5/Ran-GTP
complex and then further processed by Dicer into double-
stranded RNAs. One of the strands is degraded, and the
mature miRNA is incorporated with RISC (RNA-induced
silencing complex). miRNAs regulate gene expression
through complementary binding to the 3′ untranslated re-
gion (3′ UTR) of the targeted messenger RNA (mRNA). If
the complementary paring pattern between the miRNAand the targeted mRNA is perfect, then the mRNA is
cleaved by RISC, whereas if the paring is imperfect, then
translational repression occurs [23].
A role for miRNAs in malaria pathogenesis has been
increasingly documented. Transcriptome-wide analysis of
miRNAs in Anopheles gambiae showed the differential ex-
pression levels between blood meal and after infection by
P. berghei [24]. In sickle cell anemia, miRNAs from sickle
cells translocated into P. falciparum and inhibited parasite
growth [25]. The study of miRNA expression in ECM and
non-ECM revealed that miRNAs, e.g., let7i, miR-27a, and
miR-150, are significantly differentially expressed in the
brains of PbA-infected CBA mice [26]. miRNAs have been
reported to control the expression of genes related to
malaria pathogenesis in diverse diseases such as the inhib-
ition of ICAM-1 by miR-17-3p, VCAM-1 by miR-126, and
E-selection by miR-31 [27]. The apoptosis of endothelial
cells, neuroglial cells, and erythroid cells is regulated by
miR-29b, the miR-15-16 cluster, the let-7/miR-98 family,
and the miR-17-92 cluster [28]. NF-kB signaling is inhib-
ited by miR-181b and miR-146a [29–31]. Hypoxia is regu-
lated by miR-210 [29]. In addition, miRNA array analysis
of postmortem kidney samples from malaria patients with
acute kidney injury has also been investigated [32]. There-
fore, this evidence highlights the potential role of miRNAs
in the pathogenesis of malaria. However, the study of
miRNA in human CM is still limited. Ultimately, the
application of miRNA as inhibitor of pathogenic gene
expression should be further studied as a new approach
for adjunct CM therapy.
Treatment and prevention of CM
The early diagnosis and urgent treatment of complicated
malaria is a good practice for the prevention of CM. The
complicated malaria case must be considered as a medical
emergency and high priority of treatment. The recom-
mended antimalarial treatment for complicated malaria
including CM is water-soluble artemisinin derivative arte-
sunate. The supportive management of malaria complica-
tion is essential such as fluid and electrolyte imbalance
and convulsion. Many clinical trials studied on adjunctive
therapies for complicated malaria using exchange blood
transfusion, anti-TNF, etc. However, no effective adjunct-
ive therapies demonstrated the improvement of severity
outcome [33].
The control programs of malaria are environmental
insecticide-spraying programs, insecticide-treated bed nets,
drug treatment in the case of clinical infection, and prophy-
lactic measure for travelers. However, the major problems
of the control programs include multidrug resistance in
parasites, insecticide (pyrethroids) resistance in mosquitos,
and the lack of effective vaccines. P. falciparum resistance
to multiple drugs has been widely detected in endemic
areas. The failure of artemisinin treatment occurred in five
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Myanmar, Thailand, Vietnam, and the Lao People’s
Democratic Republic [2]. Drug resistance in the malaria
parasite is due to mutations of genes that encode the crit-
ical components of the drug target such as P. falciparum
dihydrofolate reductase (Pfdhfr) [34–38].
The current approach for malaria vaccine development
is based on the use of recombinant proteins or the attenu-
ated whole organism. However, there is no practical or ef-
fective vaccine in clinical use. The key considerations are
the delivery system, evolutionary changes in the parasites,
and the development of resistance. After vaccination,
humans have two main responses of antiparasite and anti-
toxic immunity. Vaccines are designed for various stages
of the malaria life cycle: the pre-erythrocytic-stage
vaccines for the prevention of infection, the blood-stage
vaccines for the prevention of clinical illness and death,
and the sexual stage vaccines for blocking transmission.
The most advanced candidate vaccine for P. falciparum
(RTS, S-AS01) is in phase III efficacy trials [39].
Human genetics of CM
The risk factors of CM are age, immunological status,
overall health status of the host, variation in host geno-
type, and parasite diversity [40]. The specific population
risk groups are young children in stable transmission
areas, non-immune pregnant women, semi-immune
pregnant women in areas of high transmission, people
with HIV/AIDS, and international travelers from non-
endemic areas [3]. Human genetic factors influence the
outcome of malaria severity. CM predisposition could be
explained by genetic polymorphisms of the genes
involved in malaria pathobiology. Most of the malaria-
related genes involve immunological responses and cellTable 3 Genetic variants associated with CM in Asians
No. Gene SNP/region
1 ABCA1 −477 and −320/promoter
2 CR1 intron 27, exon 22
rs9429942/promoter
3 TNF-α −308
−238, −308, −857, −863, and −1031/promoter haplo
4 TIM1 rs7702919, rs41297577, rs41297579/promoter haplot




7 PECAM-1 125 V/V and 563 N/N/coding region
8 CD36 539delAC
−14/promoter
−53/promoterreceptors. Single nucleotide polymorphisms (SNPs) in
the promoter region of the TNF-α gene are significantly
associated with susceptibility to CM in the Gambia,
Africa, Myanmar, and Thailand [41, 42]. However, vari-
ation in the genetic background of each ethnic population
contributes to the differences in the level of disease
predisposition and severity. Candidate gene-based genetic
association studies have been extensively analyzed in
various populations (Table 3).
The human genetic variations/phenotypes associated
with malaria infection are mainly demonstrated in the
host red blood cells, and the immunological components
include (1) red blood cell/hemoglobin defects such as
thalassemia, sickle cell trait, HbC, and HbE; (2) enzyme
defects such as G6PD deficiency and PK deficiency; (3)
membrane defects such as ovalocytosis; (4) the Duffy
blood group; (5) immunogenetic variants such as HLA
alleles; and (6) immunological components such as com-
plement receptor 1, NOS2, TNF-α, and the chromosome
5q31–q33 region (the cytokine region). These genetic
variants are highly detected in malaria-endemic areas as
a result of natural selection. The mechanism of protec-
tion is not yet clear. The reduction or failure of parasite
invasion/multiplication in the red blood cells, induction of
clearance by the immune system, and increased oxidative
stress are responsible for malaria protection [43, 44].
Parasite genetics of CM
Parasite genetics may also be involved in CM because P.
falciparum transforms host red cell membranes by incorp-
oration of parasite-derived proteins with the erythrocyte
cytoskeleton. The key virulence proteins are P. falciparum
erythrocyte membrane protein 1 (PfEMP1) and knob-
associated histidine-rich protein (KAHRP), which involveP value Odds ratio Population Ref.
<0.0001 5.5 Indian [51]
0.0003 3.03 Indian [52]
0.0009 0.25 Thai [53]
0.04 ND Gambia [54]
type <0.001 34.5 Myanmar [55]
ype 0.0009 0.41 Thai [56]
>0.05 ND Thai [57]
0.0042 1.39 Kenyan [58]
>0.05 Thai, Karen Myanmar [59]
<0.008 3.14 Myanmar [60]
<0.01 2.92 Thai [61]
0.04 ND Thai [62]
0.016 0.62 Thai [63]
0.05 0.68 Thai [63]
Table 4 Parasite ligands, host receptors, and clinical
consequences [61–63]
Receptor PfEMP1 domain Clinically significant
CD36 CIDR1α Uncomplicated/severe malaria
ICAM-1 DBL2/β type Cerebral malaria
CSA DBL3/γ type,
CIDR1α
Placental infection and other forms
HS DBL1α RBC rosette formation
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cell cytoskeleton. The development of PfEMP1 initiates
from the trophozoite stage, and the knob structure that is
formed adheres to the endothelial cell of the host [45, 46].
The parasite gene called “var” is extremely diverse and
encodes PfEMP1 that binds to various receptors on the
host. The var gene contains two exons encoding Duffy
binding-like (DBL), cysteine-rich interdomain region
(CIDR), N-terminal sequence (NTS), and acidic terminal
sequence (ATS) domains [47, 48]. The different domains
of PfEMP1 contribute to the variety of antigenic adhesion
molecules and are responsible for different clinical conse-
quences (Table 4). The parasite evades the host immune
system by intergenic recombination to generate genetic
variants. A substantial level of polymorphisms was
observed in Csp (circumsporozoite protein) and Msp-1
and Msp-2, which encode the merozoite surface proteins
1 and 2, respectively [49, 50]. Moreover, mutations in
genes related to treatment failure enhance the risk of CM.
Conclusions
CM is a fatal multifactorial disease, and approximately
20 % of patients will die from coma and seizure if no
effective treatment is available. Multidrug resistance is
still a problem in endemic areas, and effective vaccines
are not fully developed. Now, geneticists are exerting
extensive efforts to investigate the causative genes/
markers of CM. Because more than 60 % of human
protein-coding genes are predicted to be regulated by
miRNAs, miRNAs may be involved in the mechanism of
CM. The utilization of quantitative and qualitative ana-
lyses of miRNAs in CM will facilitate the discovery of
new interventions for diagnostic and therapeutic
purposes.
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